Regulatory Innovation: A Dialogue (Part II)
This article was originally published in RPM Report
Executive Summary
Center for Drug Evaluation & Research Deputy Director Douglas Throckmorton and AstraZeneca R&D President Martin Mackay took part in a moderated discussion of new initiatives and ideas for drug regulation during The RPM Report’s FDA/CMS Summit in Washington DC in December 2011. The first part of the dialogue focusing on drug review activities was previously published
; this second section addresses post-market activities and the impact of data from different types of clinical experience on FDA regulation. The conversation was transcribed by The RPM Report and lightly edited for clarity.
You may also be interested in...
The Inevitable Outcome: Diabetes Safety Model Expands To Weight Loss…And Beyond?
The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience – and what it might mean about regulatory expectations for other chronic drug classes in the future.
The Inevitable Outcome: Diabetes Safety Model Expands to Weight Loss…and Beyond?
The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience—and what it might mean about regulatory expectations for other chronic drug classes in the future.
CMS Wades Into the Opioid Debate
Reducing prescription drug abuse is a high priority item for several key legislators and for the Obama Administration. Proposed new rules for Medicare drug plan sponsors might help—but they also underscore the growing tension among the many different stakeholders in the pharmaceutical supply chain.